Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 1, 2016The Professional Medical JournalOpen Access

After 12 weeks of sitagliptin therapy, there was a significant reduction in hs-CRP from 4.21±0.37 mg/L to 2.16±0.23 mg/L (p<0.01) and HbA1c from 8.26±0.73% to 7.33±0.62% (p<0.01).

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does sitagliptin reduce inflammatory markers and improve lipid profiles in newly diagnosed type 2 diabetic patients with dyslipidemia?

Population

46 newly diagnosed type 2 diabetic patients with poor glycemic control and deranged lipid profile, aged…

Design

RCT, randomized (no specific method detailed)

Follow-up

12 weeks

Authors

MHMazhar HussainMGMuhammad Bilal GhafoorMHMuhammad Shahbaz Hussain

Discussion

Loading...

Member takes

Overview

May reduce inflammation markers in T2DM hyperlipidemia; leaves open clinical relevance pending larger trials.

Structured PICO

Does sitagliptin reduce inflammatory markers and improve lipid profiles in newly diagnosed type 2 diabetic patients with dyslipidemia?

P
Population
46 newly diagnosed type 2 diabetic patients with poor glycemic control (HbA1c ≥ 7.2%) and deranged lipid profile (cholesterol ≥ 200mg/dl, triglycerides ≥ 150mg/dl, LDL-C ≥ 160mg/dl, HDL-C ≤ 45mg/dl), aged 29-56 years, 63% male, from Pakistan. Key inclusion: not taking any medicine for diabetes, dyslipidemia, or inflammation.
I
Intervention
Sitagliptin 50 mg oral twice daily for 12 weeks
O
Outcome
Changes in inflammatory markers (ESR, WBC count, hs-CRP) and metabolic parameters (HbA1c, body weight, BMI, lipid profile) at 12 weekssurrogate

Sitagliptin significantly reduced subclinical inflammatory markers (hs-CRP, ESR, WBC) and improved lipid profiles and glycemic control in newly diagnosed type 2 diabetic patients with dyslipidemia.

Cite This Study

Hussain et al. (2016) studied this question.

synapsesocial.com/papers/6a763ddf6385d6f0bdb1b6a5https://doi.org/10.17957/tpmj/16.3494
View Full Paper
Ask AI
Bookmark
Share